Michael Robinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael Robinson has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Barbara Rose
Department of Infectious Diseases University of Sydney Sydney, Australia 2006
1 shared publicationC. Tomlinson
Dept. of PET and Nuclear Medicine, Royal Prince Alfred Hospital, Sydney, Australia
1 shared publication- Claire Elizabeth Wainwright
Department of Respiratory and Sleep Medicine, Queensland Children’s Hospital, South Brisbane, Queensland, Australia
1 shared publication Colin Harbour
Department of Infectious Diseases University of Sydney Sydney, Australia 2006
1 shared publication- Crystal Man Ying Lee
School of Population Health, Curtin University, Perth, Australia
1 shared publication D. L. Bailey
MRC Cyclotron Unit, Hammersmith Hospital, London, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 1 May 2003
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (5) , 2266-2267
Evidence for Spread of a Clonal Strain of Pseudomonas aeruginosa among Cystic Fibrosis Clinics
Recent advances in molecular typing techniques have led to the identification of a dominant clonal strain of Pseudomonas aeruginosa within several cystic fibrosis (CF) clinics ([2][1]-[6][2], [8][3], [9][4]). These strains have been described as “hypertransmissible,” and “patient-to-patient
- 1 May 2003
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (5) , 2266-2267
Open AccessEvidence for Spread of a Clonal Strain of Pseudomonas aeruginosa among Cystic Fibrosis Clinics
Recent advances in molecular typing techniques have led to the identification of a dominant clonal strain of Pseudomonas aeruginosa within several cystic fibrosis (CF) clinics ([2][1]-[6][2], [8][3], [9][4]). These strains have been described as “hypertransmissible,” and “patient-to-patient
- 11 March 2002
- Published by Wiley in Pediatric Pulmonology
- Vol. 33 (4) , 293-306
Mucociliary clearance in cystic fibrosis
Abnormal mucociliary clearance (MCC) is one of the central hypotheses for the development of lung disease in patients with cystic fibrosis (CF). However, attempts to demonstrate this decrease of MCC in vivo have proved to be somewhat less definitive, with the evidence barely favoring impaired clearance. Any apparent disparities are most likely due to the variety of methodologies used by different laboratories to measure MCC. The limitations of the various methodologies are examined in this review, in an attempt to better facilitate comparison of results. A number of physical and pharmacological therapies have been developed to promote mucus clearance from the CF airway. A summary of the results of interventional studies utilizing the measurement of MCC as an outcome measure is presented. Pediatr Pulmonol. 2002; 33:293‐306.
- 11 March 2002
- Published by Wiley in Pediatric Pulmonology
- Vol. 33 (4) , 293-306
Mucociliary clearance in cystic fibrosis
Abnormal mucociliary clearance (MCC) is one of the central hypotheses for the development of lung disease in patients with cystic fibrosis (CF). However, attempts to demonstrate this decrease of MCC in vivo have proved to be somewhat less definitive, with the evidence barely favoring impaired clearance. Any apparent disparities are most likely due to the variety of methodologies used by different laboratories to measure MCC. The limitations of the various methodologies are examined in this review, in an attempt to better facilitate comparison of results. A number of physical and pharmacological therapies have been developed to promote mucus clearance from the CF airway. A summary of the results of interventional studies utilizing the measurement of MCC as an outcome measure is presented. Pediatr Pulmonol. 2002; 33:293‐306.
- 1 June 2000
- Published by SAGE Publications in Journal of Aerosol Medicine
- Vol. 13 (2) , 73-86
Regional Mucociliary Clearance in Patients with Cystic Fibrosis
This paper reports on a large retrospective analysis of mucociliary clearance (MCC) studies in a group of 59 patients with cystic fibrosis (CF) and 17 age-matched healthy subjects. As many of the CF patients were studied on multiple occasions, a total of 184 patient studies are presented. MCC was measured using a radioaerosol and gamma camera technique. In addition to whole lung clearance, MCC was measured from the central, intermediate, peripheral, basal, mid and apical regions of the lung. MCC was markedly decreased in the CF patient group. Not only was whole lung clearance (14.2 ± 1.4% vs. 28.0 ± 3.7%) impaired, but also clearance from the central (19.1 ± 1.9% vs. 35.6 ± 4.3%), intermediate (10.7 ± 1.6% vs. 25.5 ± 3.7%), apical (12.4 ± 2.6% vs. 31.6 ± 4.6%) and mid (14.0 ± 1.9% vs. 30.4 ± 4.0%) regions. Attempts were made to identify factors that may have influenced MCC in both the normal subjects and CF patients. Age, gender, body mass index, patient genotype, penetration index, spontaneous cough, and various lung function parameters were entered into a stepwise multiple regression model, but none of the factors proved to be statistically important in determining MCC. Both intrasubject repeatability and intersubject variability estimates are presented for the patients and normal subjects that had multiple studies. The values were found to be remarkably similar for both CF patients and normal subjects and for both intra- and intersubject repeatability. With marked deviation from normal ranges and good repeatability, the measurement of MCC in CF patients would seem to be a valuable outcome measure for clinical trials involving new pharmaceuticals and physical therapy designed to improve removal of secretions from the airways.
- 1 June 2000
- Published by SAGE Publications in Journal of Aerosol Medicine
- Vol. 13 (2) , 73-86
Regional Mucociliary Clearance in Patients with Cystic Fibrosis
This paper reports on a large retrospective analysis of mucociliary clearance (MCC) studies in a group of 59 patients with cystic fibrosis (CF) and 17 age-matched healthy subjects. As many of the CF patients were studied on multiple occasions, a total of 184 patient studies are presented. MCC was measured using a radioaerosol and gamma camera technique. In addition to whole lung clearance, MCC was measured from the central, intermediate, peripheral, basal, mid and apical regions of the lung. MCC was markedly decreased in the CF patient group. Not only was whole lung clearance (14.2 ± 1.4% vs. 28.0 ± 3.7%) impaired, but also clearance from the central (19.1 ± 1.9% vs. 35.6 ± 4.3%), intermediate (10.7 ± 1.6% vs. 25.5 ± 3.7%), apical (12.4 ± 2.6% vs. 31.6 ± 4.6%) and mid (14.0 ± 1.9% vs. 30.4 ± 4.0%) regions. Attempts were made to identify factors that may have influenced MCC in both the normal subjects and CF patients. Age, gender, body mass index, patient genotype, penetration index, spontaneous cough, and various lung function parameters were entered into a stepwise multiple regression model, but none of the factors proved to be statistically important in determining MCC. Both intrasubject repeatability and intersubject variability estimates are presented for the patients and normal subjects that had multiple studies. The values were found to be remarkably similar for both CF patients and normal subjects and for both intra- and intersubject repeatability. With marked deviation from normal ranges and good repeatability, the measurement of MCC in CF patients would seem to be a valuable outcome measure for clinical trials involving new pharmaceuticals and physical therapy designed to improve removal of secretions from the airways.